期刊文献+

长春花碱与NVP-BEZ235联合制剂诱导人肾肿瘤细胞凋亡活性的研究

Vinblastine plus NVP-BEZ235 inducing apoptosis of human renal tumor cells
暂未订购
导出
摘要 目的作为成年人中最常见的肾癌,肾细胞癌对常规放疗和化疗均不敏感,因此急需研发新的治疗手段。长春花碱和NVP-BEZ235均用于多种癌症的治疗,但是其二者的联合治疗肾细胞癌的效果如何,仍有待研究。本文以Caki细胞系为模型,研究长春花碱与NVPBEZ235联合制剂诱导人肾肿瘤细胞凋亡的活性及可能机制。方法通过对人肾肿瘤细胞系Caki细胞系进行模拟处理(阴性对照)或者长春花碱、NVP-BEZ235以及长春花碱+NVPBEZ235处理24h后,收集细胞样品,分别通过Annexin V染色检测细胞凋亡情况;通过Western杂交检测Caspase-3以及Mcl-1蛋白表达水平,以及通过RT-PCR检测Mcl-1的RNA表达水平。结果长春花碱和NVP-BEZ235单独使用时,并不能显著诱导Caki细胞凋亡,而长春花碱+NVP-BEZ235则可以凋亡细胞比例达到60%左右。进一步的浓度梯度实验表明,二者联合使用诱导凋亡的能力与长春花碱和NVP-BEZ235的浓度呈正相关。研究表明,长春花碱和NVPBEZ235单独使用时,并不对Caspase-3的表达水平产生明显影响,而长春花碱+NVP-BEZ235联合使用时,Caspase-3的水平显著上调。对Mcl-1的检测发现,长春花碱和NVP-BEZ235单独使用和联合作用均未使Mcl-1的RNA水平产生明显变化。两种药物单独使用时,也不对Mcl-1的蛋白水平产生明显影响,但是联合使用时显著地降低了Mcl-1的蛋白表达水平。结论长春花碱与NVP-BEZ235联合制剂能够诱导人肾肿瘤细胞凋亡,并且其诱导凋亡机制与上调Caspase-3水平以及下调Mcl-1水平相关。 Objective To study the activity of Vinblastine(VLB)plus NVP-BEZ235 in inducing the apoptosis of human renal carcinoma cells and underlying mechanisms.Methods Human renal carcinoma Caki cells were separately treated with VLB,NVP-BEZ235 and VLB+NVP-BEZ235 for24 h,and apoptosis was determined by Annexin V staining,the expression levels of Caspase-3 and Mcl-1 proteins were detected by Western blotting and those of Mcl-1 mRNA by RT-PCR.Results VLB or NVP-BEZ235 alone did not induce apparent apoptosis of Caki cells,while the treatment of VLB+NVP-BEZ235 significantly enhanced apoptosis rate to about 60% in a concentrationdependent manner.The apoptosis-inducing activity of VLB+NVP-BEZ235 was correlated with the up-regulation of Caspase-3 and down-regulation of Mcl-1.Conclusions The combination of VLB and NVP-BEZ235 can induce apoptosis of human renal cell carcinoma cells,which is related to the up-regulation of Caspase-3 and down-regulation of Mcl-1.
出处 《临床肾脏病杂志》 2018年第2期115-119,共5页 Journal Of Clinical Nephrology
关键词 长春花碱 NVP-BEZ235 人肾肿瘤细胞 凋亡 Vinblastine NVP BEZ235 Human renal cell carcinoma Apoptosis
  • 相关文献

参考文献4

二级参考文献78

  • 1顾方六,肾肿瘤[M]//吴阶平.泌尿外科学.上卷.济南:山东科学技术出版社,2004:895-896.
  • 2Masuda H, Kurita Y, Suzuki A, et al. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases [J]. Urology, 1997, 4(4):247-252.
  • 3Takashi M, Kawai T, Murase T, et al. Multivariate evaluation of prognostic determinants for renal cell carcinomas which are metastatic at initial diagnosis [J]. Urol Nephrol, 1997, 29(6):291-300.
  • 4Giberti C, Oneto F, Martorana G, et al. Radical nephrectomy for renal cell carcinoma: long term results and prognostic factors on a series of 328 cases [J]. Eur Urol, 1997, 31(1) :40-48.
  • 5Gitterio G, Bertuzzi A, Tresoldi M, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients [J]. Eur Urol, 1997, 31 (8) :286-291.
  • 6Kuczyk MA, Bokemeyer C, KEhn G, et al. Prognostic relevance of intracaval noeplastic extension for patients with renal cell cancer [J]. Br J Urol, 1997, 80(1):18-24.
  • 7Wood DD. Role of lymphadenectomy in renal cell carcinoma [J]. Urol Clin North Am, 1991, 18(2):421-426.
  • 8Fisher RI, Rosenberg SA. Long-term survival update for highdose recombinant interleukin-2 in patients with renal cell carconima [J]. Cancer J Sci AM, 2000, 6(Suppl 1):SSS-S7.
  • 9Stebbing J, Gore M. The current status of interferon-alpha treatment in advanced renal cancer [J]. BJU Int, 2001, 87(7) : 599-601.
  • 10Wlihelm SM,Carter C, Tang L, et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involed in tumor progression and angiogenesis[J]. Cancer Res,2004,64(19) :7099-7109.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部